11:11 AM EDT, 05/11/2026 (MT Newswires) -- Denali Therapeutics (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday note.

The firm said first patients were treated in a commercial setting in April, with strong interest across patient segments, geographies, and disease type.

Oppenheimer said Avlayah's approval validates Denali's streamlined development approach and could support future commercialization across the company's disease pipeline.

Startup activities remain underway for a global phase 3 study of DNL126 expected to begin in H2, while patient dosing for the phase 1 DNL952 study is expected to start soon, the firm said.

Oppenheimer maintained its outperform rating and $40 price target on Denali Therapeutics.

Price: 19.92, Change: +0.30, Percent Change: +1.53